3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
8
Liver Neoplasms
5
Carcinoma, Hepatocellular
4
Lung Neoplasms
3
Squamous Intraepithelial Lesions
2
Prostatic Neoplasms
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Unresectable Pancreatic Cancer
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Rectal Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Neoplasm Metastasis
1
Melanoma
1
Lymphatic Metastasis
1
Liver, Cancer of, Non-Resectable
1
Laryngeal Neoplasms
1
Hilus Pulmonary Neoplasms
1
Head and Neck Neoplasms
1
HIV Seropositivity
1
Gallbladder Neoplasms
1
Extremities Neoplasms
1
Esophageal Neoplasms
1
Colorectal Liver Metastases
1
Carcinoma, Renal Cell
1
Interventions
Gemcitabine
34
Cisplatin
21
Capecitabine
18
Oxaliplatin
15
Leucovorin
10
Fluorouracil
10
Irinotecan
8
Erlotinib Hydrochloride
7
pembrolizumab
5
Bevacizumab
5
Radiotherapy
4
Carboplatin
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
Watchful Waiting
3
Taxes
3
Sorafenib
3
Platinum
3
Interleukin-12 Subunit p35
3
Immunohistochemistry
3
Docetaxel
3
1,2-diaminocyclohexaneplatinum II citrate
3
trifluridine tipiracil drug combination
2
tremelimumab
2
regorafenib
2
durvalumab
2
dehydroftorafur
2
Trastuzumab
2
Paclitaxel
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Gallbladder Neoplasms
×
Electroporation
×
Clear all
NCT02430662
2021-09-05
IRE
Fuda Cancer Hospital, Guangzhou
Phase NA
Completed
30 enrolled